INmune Bio treats first patient in Phase II portion of INKmune trial for metastatic prostate cancer at VA hospital

Inmune Bio, Inc.

First patient treated in Phase II portion of Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) at West LA VA Medical Center.
Patient received the medium dose of INKmune, an NK cell therapy, expanding the ongoing trial to the VA health system.
Approximately 15,000 Veterans diagnosed with prostate cancer annually; 200,000+ Veterans are survivors.
Principal investigator Dr. Matthew Rettig notes the therapy is given as outpatient with minimal side effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.